FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366998802> ?p ?o ?g. }

• W4366998802 endingPage "e200151" @default.
• W4366998802 startingPage "e200151" @default.
• W4366998802 abstract "Background and Objectives To assess the clinical practice applicability of autoimmune encephalitis (AE) criteria (2016). Methods Medical records of 538 adults diagnosed with AE or related autoimmune encephalopathy at Mayo Clinic (not including pure movement disorders) were reviewed and AE guideline criteria applied. Results Of 538 patients, 288 were male (52%). The median symptom onset age was 55 years (range, 11–97 years; 16 had onset as children). All had other non-AE diagnoses reasonably excluded. Of 538 patients, 361 (67%) met at least possible criteria, having all 3 of subacute onset; memory deficits, altered mental status or psychiatric symptoms, and ≥1 supportive feature (new focal objective CNS finding, N = 285; new-onset seizures, N = 283; supportive MRI findings, N = 251; or CSF pleocytosis, N = 160). Of 361 patients, AE subgroups were as follows: definite AE (N = 221, 61%, [87% AE-specific IgG positive]), probable seronegative AE (N = 18, 5%), Hashimoto encephalopathy (N = 20, 6%), or possible AE not otherwise categorizable (N = 102, 28%). The 221 patients with definite AE had limbic encephalitis (N = 127, 57%), anti–NMDA-R encephalitis (N = 32, 15%), ADEM (N = 8, 4%), or other AE-specific IgG defined (N = 54, 24%). The 3 most common definite AE-IgGs detected were as follows: LGI1 (76, 34%), NMDA-R (32, 16%), and high-titer GAD65 (23, 12%). The remaining 177 patients (33%) not meeting possible AE criteria had the following: seizures only (65, 12% of all 538 patients), brainstem encephalitis without supratentorial findings (55, 10%; none had Bickerstaff encephalitis), or other (57, 11%). Those 57 “others” lacked sufficient supportive clinical, radiologic, or CSF findings (N = 26), had insidious or initially episodic onset of otherwise typical disorders (N = 21), or had atypical syndromes without clearcut memory deficits, altered mental status, or psychiatric symptoms (N = 10). Fifteen of 57 were AE-specific IgG positive (26%). Among the remaining 42, evidence of other organ-specific autoimmunity (mostly thyroid) was encountered in 31 (74%, ≥1 coexisting autoimmune disease [21, 50%] or ≥1 non–AE-specific antibodies detected [23, 53%]), and all but 1 had an objective immunotherapy response (97%). Discussion The 2016 AE guidelines permit autoimmune causation assessment in subacute encephalopathy and are highly specific. Inclusion could be improved by incorporating AE-IgG–positive patients with isolated seizures or brainstem disorders. Some patients with atypical presentations but with findings supportive of autoimmunity may be immune therapy responsive." @default.
• W4366998802 created "2023-04-27" @default.
• W4366998802 creator A5028503045 @default.
• W4366998802 creator A5029649079 @default.
• W4366998802 creator A5032795537 @default.
• W4366998802 creator A5032891503 @default.
• W4366998802 creator A5048440673 @default.
• W4366998802 creator A5053780989 @default.
• W4366998802 creator A5061661448 @default.
• W4366998802 creator A5073062736 @default.
• W4366998802 creator A5084888913 @default.
• W4366998802 creator A5088136783 @default.
• W4366998802 date "2023-04-25" @default.
• W4366998802 modified "2023-09-25" @default.
• W4366998802 title "Autoimmune Encephalitis Criteria in Clinical Practice" @default.
• W4366998802 cites W1558692530 @default.
• W4366998802 cites W1979369853 @default.
• W4366998802 cites W2005575607 @default.
• W4366998802 cites W2006114544 @default.
• W4366998802 cites W2008134500 @default.
• W4366998802 cites W2012811274 @default.
• W4366998802 cites W2017184820 @default.
• W4366998802 cites W2117091873 @default.
• W4366998802 cites W2128597204 @default.
• W4366998802 cites W2129229339 @default.
• W4366998802 cites W2153997637 @default.
• W4366998802 cites W2160211535 @default.
• W4366998802 cites W2161056913 @default.
• W4366998802 cites W2280783985 @default.
• W4366998802 cites W2337989501 @default.
• W4366998802 cites W2341053399 @default.
• W4366998802 cites W2580666923 @default.
• W4366998802 cites W2618637635 @default.
• W4366998802 cites W2782339488 @default.
• W4366998802 cites W2913472312 @default.
• W4366998802 cites W2941168924 @default.
• W4366998802 cites W2953728338 @default.
• W4366998802 cites W2981598129 @default.
• W4366998802 cites W3034212049 @default.
• W4366998802 cites W3046853971 @default.
• W4366998802 cites W3109423028 @default.
• W4366998802 cites W3113688410 @default.
• W4366998802 cites W3119678414 @default.
• W4366998802 cites W3153301054 @default.
• W4366998802 cites W3193484269 @default.
• W4366998802 cites W3217562875 @default.
• W4366998802 cites W4210892653 @default.
• W4366998802 cites W4284882099 @default.
• W4366998802 cites W4286499669 @default.
• W4366998802 doi "https://doi.org/10.1212/cpj.0000000000200151" @default.
• W4366998802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37124463" @default.
• W4366998802 hasPublicationYear "2023" @default.
• W4366998802 type Work @default.
• W4366998802 citedByCount "5" @default.
• W4366998802 countsByYear W43669988022023 @default.
• W4366998802 crossrefType "journal-article" @default.
• W4366998802 hasAuthorship W4366998802A5028503045 @default.
• W4366998802 hasAuthorship W4366998802A5029649079 @default.
• W4366998802 hasAuthorship W4366998802A5032795537 @default.
• W4366998802 hasAuthorship W4366998802A5032891503 @default.
• W4366998802 hasAuthorship W4366998802A5048440673 @default.
• W4366998802 hasAuthorship W4366998802A5053780989 @default.
• W4366998802 hasAuthorship W4366998802A5061661448 @default.
• W4366998802 hasAuthorship W4366998802A5073062736 @default.
• W4366998802 hasAuthorship W4366998802A5084888913 @default.
• W4366998802 hasAuthorship W4366998802A5088136783 @default.
• W4366998802 hasBestOaLocation W43669988021 @default.
• W4366998802 hasConcept C126322002 @default.
• W4366998802 hasConcept C187212893 @default.
• W4366998802 hasConcept C203014093 @default.
• W4366998802 hasConcept C2522874641 @default.
• W4366998802 hasConcept C2777483564 @default.
• W4366998802 hasConcept C2777699746 @default.
• W4366998802 hasConcept C2778621155 @default.
• W4366998802 hasConcept C2779651940 @default.
• W4366998802 hasConcept C2781460105 @default.
• W4366998802 hasConcept C2909292722 @default.
• W4366998802 hasConcept C71924100 @default.
• W4366998802 hasConcept C83455156 @default.
• W4366998802 hasConcept C90924648 @default.
• W4366998802 hasConceptScore W4366998802C126322002 @default.
• W4366998802 hasConceptScore W4366998802C187212893 @default.
• W4366998802 hasConceptScore W4366998802C203014093 @default.
• W4366998802 hasConceptScore W4366998802C2522874641 @default.
• W4366998802 hasConceptScore W4366998802C2777483564 @default.
• W4366998802 hasConceptScore W4366998802C2777699746 @default.
• W4366998802 hasConceptScore W4366998802C2778621155 @default.
• W4366998802 hasConceptScore W4366998802C2779651940 @default.
• W4366998802 hasConceptScore W4366998802C2781460105 @default.
• W4366998802 hasConceptScore W4366998802C2909292722 @default.
• W4366998802 hasConceptScore W4366998802C71924100 @default.
• W4366998802 hasConceptScore W4366998802C83455156 @default.
• W4366998802 hasConceptScore W4366998802C90924648 @default.
• W4366998802 hasIssue "3" @default.
• W4366998802 hasLocation W43669988021 @default.
• W4366998802 hasLocation W43669988022 @default.
• W4366998802 hasLocation W43669988023 @default.
• W4366998802 hasOpenAccess W4366998802 @default.

• next